Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway

International Journal of Cancer

Volumn 130, Issue 4, 2012, Pages 967-978

  Yeramian, Andree ^a   Sorolla, Anabel ^a   Velasco, Ana ^a   Santacana, Maria ^a   Dolcet, Xavier ^a   Valls, Joan ^b   Abal, Leandre ^b   Moreno, Sara ^b   Egido, Ramõn ^a   Casanova, Josep M ^b   Puig, Susana ^c   Vilella, Ramõn ^c   Llombart Cussac, Antonio ^b   Matias Guiu, Xavier ^a   Martí, Rosa M ^b  

^a UNIVERSITY OF LLEIDA   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Akt; apoptosis; Bortezomib; melanoma; RTK; Sunitinib; survival

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BORTEZOMIB; LENTIVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; S6 KINASE; SHORT HAIRPIN RNA; SUNITINIB; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; HUMANS; INDOLES; MELANOMA; MORPHOLINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 83955161761     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26096     Document Type: Article

References (41)

1. Ibrahim N, Haluska FG,. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4: 551-79.
2. Garrido MC, Bastian BC,. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010; 130: 20-7.
3. Woodman SE, Davies MA,. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010; 80: 568-74.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
5. Tawbi H, Nimmagadda N,. Targeted therapy in melanoma. Biologics 2009; 3: 475-84.
6. Smalley KS,. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010; 130: 28-37.
7. Hocker TL, Singh MK, Tsao H,. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008; 128: 2575-95.
8. Pawson T,. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004; 116: 191-203. (Pubitemid 38167312)
9. Brychtova S, Bezdekova M, Brychta T, Tichy M,. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008; 55: 273-9.
10. Graeven U, Fiedler W, Karpinski S, Ergun S, Kilic N, Rodeck U, Schmiegel W, Hossfeld DK,. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 1999; 125: 621-9. (Pubitemid 29502343)
11. Shen SS, Zhang PS, Eton O, Prieto VG,. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003; 30: 539-47. (Pubitemid 37255550)
12. Barnhill RL, Xiao M, Graves D, Antoniades HN,. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-α receptor, but not the PDGF-β receptor, in human malignant melanoma in vivo. Br J Dermatol 1996; 135: 898-904. (Pubitemid 26397917)
13. Alexis JB, Martinez AE, Lutzky J,. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005; 15: 283-5. (Pubitemid 41127464)
14. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37. (Pubitemid 36109749)
15. Atkins M, Jones CA, Kirkpatrick P,. Sunitinib maleate. Nat Rev Drug Discov 2006; 5: 279-80.
16. Ludwig H, Khayat D, Giaccone G, Facon T,. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104: 1794-807. (Pubitemid 41513161)
17. Sorolla A, Yeramian A, Dolcet X, Perez de Santos AM, Llobet D, Schoenenberger JA, Casanova JM, Soria X, Egido R, Llombart A, Vilella R, Matias-Guiu X, et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol 2008; 158: 496-504. (Pubitemid 351239183)
18. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, Soengas MS,. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005; 65: 6294-304. (Pubitemid 40994415)
19. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282-93. (Pubitemid 40994414)
20. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C,. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005; 103: 2584-9. (Pubitemid 40800538)
21. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A,. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004; 64: 4912-8. (Pubitemid 38924537)
22. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, Schmidt B, Umbreen S, Golab J, Ludwig A, Montag C, Wiebusch L, Hagemeier C, Schadendorf D, Kloetzel PM, et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 2006; 66: 7598-605. (Pubitemid 44289216)
23. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA,. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 2006; 5: 2378-87. (Pubitemid 44530475)
24. An J, Rettig MB,. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007; 6: 61-9. (Pubitemid 46206668)
25. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88: 853-63. (Pubitemid 37128085)
26. Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, et al. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res 2006; 16: 127-35. (Pubitemid 44090045)
27. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X,. Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 2004; 204: 569-77. (Pubitemid 39585956)
28. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
29. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH,. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001; 7: 1438-45. (Pubitemid 32708700)
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
31. Radisavljevic Z,. Locus of fragility in robust breast cancer system. J Cell Biochem 2004; 92: 1020-4. (Pubitemid 44264249)
32. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H,. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5: 2522-30. (Pubitemid 44650916)
33. Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP, Taguchi H,. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006; 97: 945-51. (Pubitemid 44151278)
34. Robinson MJ, Cobb MH,. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6. (Pubitemid 27135985)
35. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M,. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22. (Pubitemid 29080340)
36. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, Fabra A,. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004; 123: 1151-61. (Pubitemid 39586840)
37. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99: 734-40.
38. Curtin JA, Pinkel D, Bastian BC,. Absence of PDGFRA mutations in primary melanoma. J Invest Dermatol 2008; 128: 488-9.
39. Lesinski GB, Benninger K, Kreiner M, Quimper M, Young G, Carson WE, III,. Bortezomib pre-treatment prolongs interferon-α-induced STAT1 phosphorylation in melanoma cells. Cancer Immunol Immunother 2009; 58: 2031-7.
40. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F,. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 2008; 216: 698-707.
41. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S,. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005; 106: 4322-9. (Pubitemid 41775943)